Fluicell AB Secures Major Licensing Deal with Ambusol for Cancer Treatment Innovation
Fluicell AB has entered into a lucrative licensing agreement with Ambusol AB, valued at up to 142 million SEK, to develop a new catheter technology for cancer treatment using Fluicell’s microfluidics platform.
2 minutes to read